{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:53:43Z","timestamp":1781729623907,"version":"3.54.5"},"reference-count":79,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:p>The treatment landscape for relapsed\/refractory multiple myeloma has been transformed by the approval of T-cell\u2013redirecting bispecific antibodies (BsAbs) targeting B-cell maturation antigen (teclistamab, elranatamab, and linvoseltamab) and GPRC5D (talquetamab). Although pivotal trials have demonstrated deep and durable responses, the rapid transition of these off-the-shelf agents from controlled clinical settings to routine oncologic practice presents significant operational and clinical challenges. This review focuses on the practical framework required to deliver BsAb therapy safely and effectively across academic and community settings. We address critical components of patient selection and effective implementation strategies, including infrastructure for the management of unique short-term toxicities such as cytokine release syndrome and immune effector cell\u2013associated neurotoxicity syndrome, and long-term infection risks. We discuss models for outpatient implementation of these agents including the use of technology and academic-community partnerships (shared care models). As BsAbs move into earlier lines of therapy and combination regimens, optimizing these practical management strategies is essential to ensuring equitable access and maximizing long-term outcomes for patients with multiple myeloma.<\/jats:p>","DOI":"10.1200\/op-26-00159","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:59:08Z","timestamp":1781726348000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Practical Management of Bispecific Antibodies in Multiple Myeloma"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2594","authenticated-orcid":true,"given":"Carlyn Rose","family":"Tan","sequence":"first","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-4318","authenticated-orcid":true,"given":"Neha","family":"Korde","sequence":"additional","affiliation":[{"name":"Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":true,"given":"Hira","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022432"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01139-y"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1872"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34756"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35107"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514663"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.136"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00385-5"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7528"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71276"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016613"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01259-z"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02154-5"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2446617"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071235"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025015973"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016059"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06689-0"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70120"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206178"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552251341235"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00283-0"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286118"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514752"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19505"},{"key":"e_1_3_6_33_2","first-page":"8425047","article-title":"A case report supporting the use of teclistamab in multiple myeloma with CNS involvement","volume":"2025","author":"Blackman J","year":"2025","unstructured":"Blackman J, Blackman JT, Pauranik A, et al: A case report supporting the use of teclistamab in multiple myeloma with CNS involvement. Case Rep Hematol 2025:8425047, 2025","journal-title":"Case Rep Hematol"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1630146"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015344"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210189"},{"key":"e_1_3_6_37_2","article-title":"Defining the rates of cytokine release syndrome associated with talquetamab step-up doses","author":"Hamadeh IS","unstructured":"Hamadeh IS, Modelevsky L, Chan A, et al: Defining the rates of cytokine release syndrome associated with talquetamab step-up doses. JCO Oncol Pract 10.1200\/OP-25-00224 [epub ahead of print on September 16, 2025]","journal-title":"JCO Oncol Pract"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182166"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206357"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012724"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011225"},{"key":"e_1_3_6_42_2","article-title":"Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1\/2 MajesTEC-1 study of teclistamab in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"van de Donk Alg NWCJ","year":"2024","unstructured":"van de Donk Alg NWCJ, Benboubker L, Uttervall K, et al: Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1\/2 MajesTEC-1 study of teclistamab in relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol 42, 2024 (suppl 16; abstr 7517)","journal-title":"J Clin Oncol"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016911"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.132"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-718"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2210"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159381"},{"key":"e_1_3_6_48_2","unstructured":"NCCN: NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 4.2026. 2025. https:\/\/www.nccn.org"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179727"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01471-4"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.11146"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP-24-00489"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2751"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.04.002"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP-24-00930"},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14444"},{"key":"e_1_3_6_57_2","volume-title":"TECVAYLI (Teclistamab-cqyv) Injection, for Subcutaneous Use: Prescribing Information","author":"Administration USFaD","year":"2024","unstructured":"Administration USFaD: TECVAYLI (Teclistamab-cqyv) Injection, for Subcutaneous Use: Prescribing Information. Silver Spring, MD, 2024"},{"key":"e_1_3_6_58_2","volume-title":"TALVEY (Talquetamab-tgvs) Injection, for Subcutaneous Use: Prescribing Information","author":"Administration USFaD","year":"2025","unstructured":"Administration USFaD: TALVEY (Talquetamab-tgvs) Injection, for Subcutaneous Use: Prescribing Information. Titusville, NJ, 2025"},{"key":"e_1_3_6_59_2","volume-title":"LYNOZYFIC (Linvoseltamab-gcpt) Injection, for Subcutaneous Use: Prescribing Information","author":"Administration USFaD","year":"2024","unstructured":"Administration USFaD: LYNOZYFIC (Linvoseltamab-gcpt) Injection, for Subcutaneous Use: Prescribing Information. Tarrytown, NY, 2024"},{"key":"e_1_3_6_60_2","volume-title":"ELREXFIO (Elranatamab-bcmm) Injection, for Subcutaneous Use: Prescribing Information","author":"Administration USFaD","year":"2024","unstructured":"Administration USFaD: ELREXFIO (Elranatamab-bcmm) Injection, for Subcutaneous Use: Prescribing Information. New York, NY, 2024"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z"},{"key":"e_1_3_6_62_2","volume-title":"22nd Annual International Myeloma Society Meeting and Exposition, Toronto, Canada","author":"Mian HS","year":"2025","unstructured":"Mian HS, Riley CH, Popat R, et al: PRe: Cevostamab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Phase Ib CAMMA-1 dose-expansion results, 22nd Annual International Myeloma Society Meeting and Exposition, Toronto, Canada, 2025"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18909"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00966-9"},{"key":"e_1_3_6_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01342-5"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02482-6"},{"key":"e_1_3_6_68_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3333"},{"key":"e_1_3_6_69_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026212"},{"key":"e_1_3_6_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00186-8"},{"key":"e_1_3_6_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_3_6_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8"},{"key":"e_1_3_6_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01314-9"},{"key":"e_1_3_6_74_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012773"},{"key":"e_1_3_6_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504"},{"key":"e_1_3_6_76_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199542"},{"key":"e_1_3_6_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7514"},{"key":"e_1_3_6_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000983"},{"key":"e_1_3_6_79_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-2135"},{"key":"e_1_3_6_80_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207674"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-26-00159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T19:59:11Z","timestamp":1781726351000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-26-00159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":79,"alternative-id":["10.1200\/OP-26-00159"],"URL":"https:\/\/doi.org\/10.1200\/op-26-00159","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2026-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-26-00159"}}